Metastatic Disease: Clinical Trials

17 trials for Metastatic Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 terminated, 4 completed, 2 not yet recruiting, 2 recruiting. 17 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 217Terminated 7, Completed 4, Not yet recruiting 2, Recruiting 2, Withdrawn 2
Phase 12Recruiting 1, Terminated 1
Phase 31Withdrawn 1

Follow Metastatic Disease: new trials by email Literature Review of Metastatic Disease trials Research Report on Metastatic Disease

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma
mFOLFIRINOX versus FOLFOX chemotherapy - Small-bowel Adenocarcinoma, Metastatic Disease
Phase 2Not yet recruitingAnnika Kurreck862026-10-012026-09-28
Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck
Zanzalintinib - Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence
Phase 2Not yet recruitingUNICANCER512026-10-012026-07-06
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy) - Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced
Phase 1 / Phase 2RecruitingBeijing Biotech422026-03-022026-06-04
OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites
stereotactic radiation therapy in ablative doses to each metastatic site - Metastatic Disease
Phase 2RecruitingNational Medical Research Radiological Centre of the Ministry of Health of Russia502025-02-072025-03-04
IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study
Darleukin, Radiation - NSCLC Stage IV, Metastatic Disease
Phase 2TerminatedMaastricht University Medical Center882019-04-042025-01-30
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Melanoma vaccine modified to express HLA A2/4-1BB ligand - High Risk HLA-A2+ Melanoma, Metastatic Disease
Phase 2 / Phase 3WithdrawnHadassah Medical Organization2017-03-012025-10-02
Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)
Nintedanib, Fluorouracil, Leucovorin - Esophagogastric Adenocarcinoma, Metastatic Disease
Phase 2WithdrawnEuropean Organisation for Research and Treatment of Cancer - EORTC2016-12-012017-05-09
Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
Regorafenib - Colorectal Neoplasms, Metastatic Disease
Phase 2TerminatedSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)152014-06-012017-08-01
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
Regorafenib - Colorectal Neoplasms, Metastatic Disease
Phase 2CompletedSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)462013-06-012017-08-01
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
Arm A chemotherapy, arm B chemotherapy - Adenocarcinoma of Colon, Adenocarcinoma of Rectum
Phase 2CompletedCentro Nacional de Investigaciones Oncologicas CARLOS III292012-11-012015-10-09
Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy
AUY922 - Adenocarcinoma of the Pancreas, Metastatic Disease
Phase 2TerminatedUniversity Health Network, Toronto152012-01-012019-02-15
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
Itraconazole - Prostate Cancer, Prostatic Neoplasms
Phase 2TerminatedStanford University42010-09-012017-04-11
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Temsirolimus, Casodex (bicalutamide) - Prostate Cancer, Prostatic Neoplasms
Phase 1 / Phase 2TerminatedSandy Srinivas52009-10-012014-10-13
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Nilotinib, Nilotinib with Imatinib - GIST, Metastatic Disease
Phase 2TerminatedFox Chase Cancer Center52009-02-012017-03-15
Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal
Sorafenib - Renal Cell Carcinoma, Metastatic Disease
Phase 2CompletedUniversity Health Network, Toronto192007-05-012015-12-09
Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)
Nexavar (Sorafenib), IL-2 - Metastatic Disease, Renal Cell Carcinoma
Phase 2CompletedItalian Trial in Medical Oncology902006-11-012009-02-26
Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen
Tamoxifen - Breast Cancer, Metastatic Disease
Phase 2TerminatedNational Cancer Center, Korea212006-06-012010-02-10

Narrower conditions

Neoplasm Metastasis (17)  ·  Carcinoma, Renal Cell (2)  ·  Colorectal Neoplasms (2)  ·  Pancreatic Neoplasms (2)  ·  Prostatic Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colonic Neoplasms (1)  ·  Melanoma (1)  ·  Rectal Neoplasms (1)  ·  Recurrence (1)

Broader conditions

Neoplasms (17)  ·  Neoplastic Processes (17)  ·  Pathologic Processes (17)  ·  Pathological Conditions, Signs and Symptoms (17)  ·  Neoplasms by Site (12)  ·  Digestive System Diseases (5)  ·  Digestive System Neoplasms (5)  ·  Male Urogenital Diseases (4)  ·  Urogenital Diseases (4)  ·  Urogenital Neoplasms (4)  ·  Colonic Diseases (3)  ·  Gastrointestinal Diseases (3)  ·  Gastrointestinal Neoplasms (3)  ·  Intestinal Diseases (3)  ·  Intestinal Neoplasms (3)

Interventions

Sorafenib (3)  ·  Fluorouracil (2)  ·  Oxaliplatin (2)  ·  regorafenib (2)  ·  5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide (1)  ·  Capecitabine (1)  ·  Cetuximab (1)  ·  Cisplatin (1)  ·  Cyclophosphamide (1)  ·  Dasatinib (1)  ·  Docetaxel (1)  ·  Doxorubicin (1)  ·  Erlotinib Hydrochloride (1)  ·  Etoposide (1)  ·  Gemcitabine (1)

Sponsors

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) (2)  ·  University Health Network, Toronto (2)  ·  Annika Kurreck (1)  ·  Beijing Biotech (1)  ·  Centro Nacional de Investigaciones Oncologicas CARLOS III (1)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  Fox Chase Cancer Center (1)  ·  Hadassah Medical Organization (1)  ·  Italian Trial in Medical Oncology (1)  ·  Maastricht University Medical Center (1)  ·  National Cancer Center, Korea (1)  ·  National Medical Research Radiological Centre of the Ministry of Health of Russia (1)  ·  Sandy Srinivas (1)  ·  Stanford University (1)  ·  UNICANCER (1)

Countries

Spain (3)  ·  United States (3)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Belgium (1)  ·  China (1)  ·  Netherlands (1)  ·  Russia (1)  ·  South Korea (1)  ·  United Kingdom (1)

Top investigators

A. Ardizzoia, MD (1)  ·  A. Bertolini, MD (1)  ·  Alfredo Carrato, MD-PhD (1)  ·  Andrey Kaprin, PhD (1)  ·  Annika Kurreck, PD Dr. (1)  ·  Antonio Finelli, MD,MSc,FRCSC (1)  ·  C. Porta, MD (1)  ·  D. Amadori, MD (1)  ·  Dr. Sandy Srinivas (1)  ·  E. Aitini, MD (1)  ·  Enrique Grande, MD (1)  ·  G. Conti, MD (1)  ·  G. Fasola, MD (1)

Results publications

PMID 24063860, PMID 30120161, PMID 32539805, PMID 33688020, PMID 37146227

NIH funding

2014 (1), 2016 (1)